Immunic Inc Asset Resilience Ratio
Immunic Inc asset resilience ratio. Immunic Inc (IMUX) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Immunic Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Immunic Inc (2012–2023)
Asset resilience ratio of Immunic Inc from 2012 to 2023. This chart shows how Immunic Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Immunic Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Immunic Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Immunic Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Immunic Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Immunic Inc Industry Peers by Asset Resilience Ratio
Compare Immunic Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Immunic Inc Asset Resilience Ratio by Year (2012–2023)
Immunic Inc asset resilience ratio by year from 2012 to 2023. The table below shows the annual Asset Resilience Ratio data for Immunic Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $54.30 Million | -- |
| 2022-12-31 | 7.54% | $9.63 Million | $127.75 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $139.10 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $60.38 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $64.03 Million | -- |
| 2012-12-31 | 68.84% | $14.00 Million | $20.33 Million | -- |
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative… Read more